Refractory Melanoma
Showing 1 - 10 of 10
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in
Not yet recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +4 more
- Rigosertib
- +4 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Feb 28, 2023
Malignant Solid Tumor, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma Trial in Puerto Rico, United States
Recruiting
- Malignant Solid Neoplasm
- +40 more
- Biospecimen Collection
- +6 more
-
Birmingham, Alabama
- +172 more
Jan 27, 2023
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in
Active, not recruiting
- Metastatic Melanoma
- +22 more
- Ipilimumab
- +3 more
-
Birmingham, Alabama
- +24 more
Jan 19, 2023
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Tumor Trial in Canada,
Active, not recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +20 more
- Pembrolizumab
- Ziv-Aflibercept
-
Tampa, Florida
- +8 more
Jan 3, 2023
HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1
Recruiting
- HLA-A2 Positive Cells Present
- Refractory Melanoma
- Alpha-type-1 Polarized Dendritic Cells
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 12, 2022
Advanced Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma Trial in United States (Ipilimumab, Nivolumab)
Active, not recruiting
- Advanced Melanoma
- +10 more
- Ipilimumab
- Nivolumab
-
Anchorage, Alaska
- +638 more
Aug 30, 2022
NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma Trial in Pittsburgh (Pixatimod, Nivolumab, Cyclophosphamide (low
Recruiting
- NSCLC
- +2 more
- Pixatimod
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Mar 28, 2022
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Tumor Trial in Houston
Recruiting
- Advanced Endometrial Carcinoma
- +36 more
- Glutaminase Inhibitor IPN60090
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Sep 9, 2021